MHRA Grants Marketing Authorisation for Global Blood Therapeutics’s Oxbryta (Voxelotor)
Summary: Voxelotor is the first medicine in Britain to directly inhibit sickle haemoglobin polymerisation Global Blood Therapeutics (GBT) has announced that the…
Summary: Voxelotor is the first medicine in Britain to directly inhibit sickle haemoglobin polymerisation Global Blood Therapeutics (GBT) has announced that the…
Summary – Drug firm Marksans Pharma on Thursday said its subsidiary has received market authorisation from the UK health regulator for its…